News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Aug 07, 2017
- Epidiolex® NDA submission process underway – - Conference call today at 4:30 p.m. EST -
Jul 24, 2017
London, UK,  24 July 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2017 its th
Jun 07, 2017
London, UK, 7 June 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that GW management will
May 24, 2017
– Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control –
May 15, 2017
- Dr. Volker Knappertz appointed Chief Medical Officer - - Professor Ben Whalley to join as Head of Discovery Research -
May 09, 2017
- Epidiolex® NDA submission expected mid-year– - New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology -
May 05, 2017
London, UK, 5 May 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s C
May 02, 2017
London, UK,  2 May 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 May, 2017 its second

Pages